Merck’s PD-1/VEGF Data Star in Stacked Lineup of AACR ‘26 Data Reveals

Why It Matters

Successful MK‑2010 results could re‑establish Merck as a leader in checkpoint‑plus‑angiogenesis therapy, reshaping competitive dynamics in immuno‑oncology. Simultaneously, the rise of RAS inhibitors and next‑generation antibody conjugates signals a broader industry pivot toward precision modalities that may unlock new revenue streams.

Key Takeaways

• Merck to present first‑in‑human MK‑2010 data at AACR 2026.
• MK‑2010 licensed from LaNova for $588 M upfront in 2024.
• RAS‑targeted small molecules zoldonrasib and elisrasib show promising early responses.
• ADCs and DACs debut dual‑payload and degradation strategies at the meeting.
• Industry deals include $185 M GSK‑Hansoh ADC license and $1 B Roche‑C4 DAC pact.

Pulse Analysis

Merck’s spotlight at AACR 2026 will be the first‑in‑human readout of MK‑2010, a bispecific antibody that simultaneously blocks PD‑1 and VEGF. The molecule, licensed from Shanghai‑based LaNova Medicines for an upfront $588 million in 2024, is Merck’s answer to the recent success of ivonescimab, which outperformed Keytruda in a head‑to‑head trial. By targeting both immune checkpoint inhibition and angiogenesis, MK‑2010 aims to create a more durable anti‑tumor response across solid tumors. Investors will be watching the safety and early efficacy signals to gauge whether Merck can reclaim a leadership position in the crowded checkpoint‑inhibitor market.

The AACR program also highlights the rapid maturation of allele‑specific RAS inhibitors. Revolution Medicines’ zoldonrasib, which homes in on the KRAS‑G12D mutation, reported a 61 % objective response rate in a Phase 1 NSCLC cohort, while D3 Bio’s elisrasib targets KRAS‑G12C and showed a 30 % response in heavily pre‑treated patients. Merck’s rumored $30 billion bid for Revolution underscores the strategic value of small‑molecule RAS drugs as potential backbone therapies. As multiple agents move toward late‑stage trials, clinicians anticipate a diversified arsenal that could finally translate KRAS biology into consistent patient benefit.

Beyond bispecifics and small molecules, the conference signals a paradigm shift in antibody‑based modalities. Traditional ADCs continue to evolve, with companies like Astellas and Duality Biologics testing dual‑payload designs to improve tumor selectivity and reduce toxicity. At the same time, degrader‑antibody conjugates (DACs) are gaining traction; Roche’s up‑to‑$1 billion partnership with C4 Therapeutics and GSK’s $185 million ADC license from Hansoh illustrate the capital flowing into these next‑generation platforms. The convergence of multispecific antibodies, novel payloads, and targeted protein degradation suggests a broader industry move toward precision oncology solutions that can address resistance mechanisms and expand therapeutic windows.